Gene signature-guided drug screening identified narciclasine as a potential therapeutic for interstitial fibrosis of the kidney
Kidney International · 2025
DOI: 10.1016/j.kint.2025.03.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2025. Verfasst von An Xiao und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory for Prevention and Treatment of Multi-organ Injury, National Clinical Research Center of Kidney Disease, Division of Nephrolo…. Hauptthemen laut MEDLINE: Amaryllidaceae Alkaloids, Phenanthridines, Renal Insufficiency, Chronic, Kidney. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Peking University First Hospital.
Abstract (Originalsprache)
INTRODUCTION: Chronic Kidney Disease (CKD) is marked by progressive tubulointerstitial fibrosis (TIF), a pathological feature insufficiently addressed by existing therapies. METHODS: To identify drugs with potential to halt TIF progression, we constructed a TIF-specific gene expression signature using published human CKD kidney transcriptome data and employed the small molecule perturbant library LINCS L1000 database for a high-throughput screening of compounds capable of reversing the expression of TIF-related genes. RESULTS: Narciclasine, a natural compound derived from the Narcissus (amaryllis) plant, was identified as a top compound which significantly reversed the gene expression signature of TIF. Administration of narciclasine not only significantly prevented inflammation and fibrotic lesions induced by unilateral ureteral obstruction and unilateral ischemia-reperfusion injury but also delayed the progression of established TIF induced by unilateral ureteral obstruction. Furthermore, in the 5/6 nephrectomy-induced CKD model, narciclasine significantly lowered serum creatinine, reduced proteinuria, and alleviated TIF and inflammation. CONCLUSIONS: Mechanistically, narciclasine reversed the failed-repair phenotype of tubular epithelial cells and inhibited fibroblasts proliferation and activation, at least partially via inhibiting the activation of NF-κB signaling. Our findings suggest that narciclasine should be further investigated as a promising drug candidate to attenuate CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory for Prevention and Treatment of Multi-organ Injury, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- National Key Laboratory for Prevention and Treatment of Multi-organ Injury, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China; B…
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Peking University First Hospital
Zitieren
APA
Xiao, A., Chen, X., Ma, J., Chen, X., Long, T., Ma, Y., Chen, Q., Su, Z., Hu, Z., Xie, L., Zhang, L., Zhu, F., & Nie, J. (2025). Gene signature-guided drug screening identified narciclasine as a potential therapeutic for interstitial fibrosis of the kidney. Kidney International. https://doi.org/10.1016/j.kint.2025.03.021
Vancouver
Xiao A, Chen X, Ma J, Chen X, Long T, Ma Y, et al. Gene signature-guided drug screening identified narciclasine as a potential therapeutic for interstitial fibrosis of the kidney. Kidney International. 2025. doi:10.1016/j.kint.2025.03.021
BibTeX
@article{Xiao2025,
author = {Xiao, An and Chen, Xiaoer and Ma, Jingyi and Chen, Xiaomei and Long, Tantan and Ma, Yuanyuan and Chen, Qingzhou and Su, Zhiyuan and Hu, Zheng and Xie, Liling and Zhang, Lei and Zhu, Fengxin and Nie, Jing},
title = {Gene signature-guided drug screening identified narciclasine as a potential therapeutic for interstitial fibrosis of the kidney},
journal = {Kidney International},
year = {2025},
doi = {10.1016/j.kint.2025.03.021}
}
EUVIMED